[1]
Dakin, H.D.; Dudley, H.W. An enzyme concerned with the formation of hydroxy acids from ketonic aldehydes. J. Biol. Chem., 1913, 14(2), 155-157.
[2]
Neuberg, C. The destruction of lactic aldehyde and methylglyoxal by animal organs. Biochem. Z., 1913, 49, 502-506.
[3]
Warburg, O.; Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol., 1927, 8(6), 519-530.
[4]
Racker, E. The mechanism of action of glyoxalase. J. Biol. Chem., 1951, 190(2), 685-696.
[5]
Davis, K.A.; Williams, G.R. Cation activation of glyoxalase I. Biochimica et Biophysica Acta (BBA) –. Enzymol. Biol. Oxidat., 1966, 113(2), 393-395.
[6]
Aronsson, A-C.; Marmstål, E.; Mannervik, B.; Glyoxalase, I. a zinc metalloenzyme of mammals and yeast. Biochem. Biophy. Res. Communicat., 1978, 81(4), 1235-1240.
[7]
Vince, R.; Wadd, W.B. Glyoxalase inhibitors as potential anticancer agents. Biochem. Biophy. Res. Communicat., 1969, 35(5), 593-598.
[8]
Apple, M.; Greenberg, D. Arrest of cancer in mice by therapy with normal metabolites. II. Indefinite survirors among mice treated with mixtures of 2-oxopropanal (NSC-79019) and 2, 3-dihydroxypropanal (NSC67934). Cancer Chemother. Rep., 1968, 52(7), 687.
[9]
Együud, L.G.; Szent-Györgyi, A. Cancerostatic action of methylglyoxal. Science, 1968, 160(3832), 1140.
[10]
Conroy, P.J. In Carcinostatic activity of methylglyoxal and related substances in tumour-bearing mice, Submolecular Biology and Cancer Ciba Foundation Symposium, 1979, pp. 271-298.
[11]
Elvin, P.; Slater, T.F. Anti-tumour activity of novel adducts of ascorbic acid with aldehydes. Europ. J. Cancer Clin. Oncol., 1981, 17(7), 759-765.
[12]
Cameron, A.D.; Ridderström, M.; Olin, B.; Kavarana, M.J.; Creighton, D.J.; Mannervik, B. Reaction mechanism of glyoxalase I explored by an X-ray crystallographic analysis of the human enzyme in complex with a transition state analogue. Biochemistry, 1999, 38(41), 13480-13490.
[13]
Feierberg, I. >
Computational Studies of Enzymatic Enolization Reactions and Inhibitor Binding to a Malarial Protease. Acta Universitatis Upsaliensis, 2003.
[14]
Holewinski, R.J. Active site directed covalent modification of human glyoxalase I; Ph.D., University of Maryland, Baltimore County, Ann Arbor, 2009.
[15]
Himo, F.; Siegbahn, P.E. Catalytic mechanism of glyoxalase I: A theoretical study. J. Am. Chem. Soc., 2001, 123(42), 10280-10289.
[16]
Phillips, S.A.; Thornalley, P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur. J. Biochem., 1993, 212(1), 101-105.
[17]
Reichard, G.A., Jr; Skutches, C.L.; Hoeldtke, R.D.; Owen, O.E. Acetone metabolism in humans during diabetic ketoacidosis. Diabetes, 1986, 35(6), 668-674.
[18]
Lyles, G.A.; Chalmers, J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem. Pharmacol., 1992, 43(7), 1409-1414.
[19]
Vander Jagt, D.L.; Hunsaker, L.A. Methylglyoxal metabolism and diabetic complications: Roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem. Biol. Interact., 2003, 143-144, 341-351.
[20]
Thornalley, P.J.; Langborg, A.; Minhas, H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J., 1999, 344(Pt 1), 109-116.
[21]
Rulli, A.; Carli, L.; Romani, R.; Baroni, T.; Giovannini, E.; Rosi, G.; Talesa, V. Expression of glyoxalase I and II in normal and breast cancer tissues. Breast Cancer Res. Treat., 2001, 66(1), 67-72.
[22]
Phillips, S.A.; Thornalley, P.J. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Europ. J. Biochem. FEBS, 1993, 212(1), 101-105.
[23]
Chan, W.H.; Wu, H.J.; Shiao, N.H. Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. J. Cell. Biochem., 2007, 100(4), 1056-1069.
[24]
Thornalley, P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease. Drug Metabol. Drug Interact., 2008, 23(1-2), 125-150.
[25]
Belanger, M.; Yang, J.; Petit, J.M.; Laroche, T.; Magistretti, P.J.; Allaman, I. Role of the glyoxalase system in astrocyte-mediated neuroprotection. J. Neurosci., 2011, 31(50), 18338-18352.
[26]
Rabbani, N.; Shaheen, F.; Anwar, A.; Masania, J.; Thornalley, P.J. Assay of methylglyoxal-derived protein and nucleotide AGEs; Portland Press Limited, 2014.
[27]
Rabbani, N.; Thornalley, P.J. Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome. Amino acids, 2012, 42(4), 1133-1142.
[28]
Talukdar, D.; Chaudhuri, B.S.; Ray, M.; Ray, S. Critical evaluation of toxic versus beneficial effects of methylglyoxal. Biochem. Biokhimiia, 2009, 74(10), 1059-1069.
[29]
McLellan, A.C.; Thornalley, P.J. Glyoxalase activity in human red blood cells fractioned by age. Mechanis. Ageing Develop., 1989, 48(1), 63-71.
[30]
Rabbani, N.; Xue, M.; Thornalley, P.J. Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics. Glycoconj. J., 2016, 33(4), 513-525.
[31]
Frandsen, J.R.; Narayanasamy, P. Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway. Redox Biol., 2018, 14, 465-473.
[32]
Thornalley, P.J.; Battah, S.; Ahmed, N.; Karachalias, N.; Agalou, S.; Babaei-Jadidi, R.; Dawnay, A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem. J., 2003, 375(3), 581-592.
[33]
Santarius, T.; Bignell, G.R.; Greenman, C.D.; Widaa, S.; Chen, L.; Mahoney, C.L.; Butler, A.; Edkins, S.; Waris, S.; Thornalley, P.J. GLO1—a novel amplified gene in human cancer. Genes Chromosom Cancer, 2010, 49(8), 711-725.
[34]
Xue, M. Rabbani, N.; Thornalley, P.J. In: Glyoxalase in ageing, Seminars in cell & developmental biology; Elsevier, 2011; pp. 293-301.
[35]
Maessen, D.E.; Stehouwer, C.D.; Schalkwijk, C.G. The role of methylglyoxal and the glyoxalase system in diabetes and other agerelated diseases. Clin. Sci.(London, England : 1979), 2015, 128(12), 839-861.
[36]
Kuhla, B.; Boeck, K.; Schmidt, A.; Ogunlade, V.; Arendt, T.; Münch, G.; Lüth, H-J. Age-and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer’s disease brains. Neurobiol. Aging, 2007, 28(1), 29-41.
[37]
Chen, F.; Wollmer, M.A.; Hoerndli, F.; Münch, G.; Kuhla, B.; Rogaev, E.I.; Tsolaki, M.; Papassotiropoulos, A.; Götz, J. Role for glyoxalase I in Alzheimer’s disease. Proceed. Nat. Acad. Sci. USA, 2004, 101(20), 7687-7692.
[38]
Thornalley, P. Modification of the human red blood cell glucose system by glucose in vitro. Biochem. J., 1988, 254, 751-755.
[39]
Atkins, T.; Thornalley, P. Glyoxalase activity in tissues of lean (HO) and genetically obese diabetic (ob/ob) mice. Med. Sci. Res., 1989, 17, 777-778.
[40]
Atkins, T.; Thornalley, P. Modification of the red blood cell glyoxalase system in genetically (ob/ob) and streptozotocin induced diabetic mice. Diabetes Res., 1989, 11, 125-129.
[41]
Phillips, S.A.; Mirrlees, D.; Thornalley, P.J. Modification of the glyoxalase system in streptozotocin-induced diabetic rats: effect of the aldose reductase inhibitor Statil. Biochem. Pharmacol., 1993, 46(5), 805-811.
[42]
McLellan, A.C.; Thornalley, P.J.; Benn, J.; Sonksen, P.H. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. , 1994, 87(1), 21-29.
[43]
Giacco, F.; Du, X.; D’Agati, V.D.; Milne, R.; Sui, G.; Geoffrion, M.; Brownlee, M. Knockdown of Glyoxalase 1 Mimics Diabetic Nephropathy in Nondiabetic Mice. Diabetes, 2014, 63(1), 291-299.
[44]
Rabbani, N.; Thornalley, P.J. Glyoxalase 1 Modulation in Obesity and Diabetes. Antioxid. Redox Signal., 2018.
[45]
Matafome, P.; Rodrigues, T.; Sena, C.; Seica, R. Methylglyoxal in Metabolic Disorders: Facts, Myths, and Promises. Med. Res. Rev., 2017, 37(2), 368-403.
[46]
Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer, 2004, 4(11), 891-899.
[47]
Tennant, D.A.; Duran, R.V.; Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer, 2010, 10(4), 267-277.
[48]
Geng, X.; Ma, J.; Zhang, F.; Xu, C. Glyoxalase I in tumor cell proliferation and survival and as a potential target for anticancer therapy. Oncol. Res. Treat., 2014, 37(10), 570-574.
[49]
Thornalley, P.J.; Rabbani, N. Glyoxalase in tumourigenesis and multidrug resistance. Seminars Cell Develop.Biol., 2011, 22(3), 318-325.
[50]
Mearini, E.; Romani, R.; Mearini, L.; Antognelli, C.; Zucchi, A.; Baroni, T.; Porena, M.; Talesa, V.N. Differing expression of enzymes of the glyoxalase system in superficial and invasive bladder carcinomas. Europ. J. Cancer(Oxford, England : 1990) , 2002, 38(14), 1946 -1950.
[51]
Hosoda, F.; Arai, Y.; Okada, N.; Shimizu, H.; Miyamoto, M.; Kitagawa, N.; Katai, H.; Taniguchi, H.; Yanagihara, K.; Imoto, I. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene, 2015, 34(9), 1196-1206.
[52]
Cheng, W-L.; Tsai, M-M.; Tsai, C-Y.; Huang, Y-H.; Chen, C-Y.; Chi, H-C.; Tseng, Y-H.; Chao, I-W.; Lin, W-C.; Wu, S-M. Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One, 2012, 7(3), e34352.
[53]
Wang, Y.; Kuramitsu, Y.; Tokuda, K.; Okada, F.; Baron, B.; Akada, J.; Kitagawa, T.; Nakamura, K. Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma. Electrophoresis, 2014, 35(15), 2195-2202.
[54]
Wang, Y.; Kuramitsu, Y.; Ueno, T.; Suzuki, N.; Yoshino, S.; Iizuka, N.; Akada, J.; Kitagawa, T.; Oka, M.; Nakamura, K.; Glyoxalase, I. GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues. Anticancer Res., 2012, 32(8), 3219-3222.
[55]
Chen, Y.; Fang, L.; Li, G.; Zhang, J.; Li, C.; Ma, M.; Guan, C.; Bai, F.; Lyu, J.; Meng, Q.H. Synergistic inhibition of colon cancer growth by the combination of methylglyoxal and silencing of glyoxalase I mediated by the STAT1 pathway. Oncotarget, 2017, 8(33), 54838-54857.
[56]
Burdelski, C.; Shihada, R.; Hinsch, A.; Angerer, A.; Gobel, C.; Friedrich, E.; Hube-Magg, C.; Burdak-Rothkamm, S.; Kluth, M.; Simon, R.; Moller-Koop, C.; Sauter, G.; Buscheck, F.; Wittmer, C.; Clauditz, T.S.; Krech, T.; Tsourlakis, M.C.; Minner, S.; Graefen, M.; Schlomm, T.; Wilczak, W.; Jacobsen, F. High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77(15), 1528-1538.
[57]
Dong, L.; Zhou, Q.; Zhang, Z.; Zhu, Y.; Duan, T.; Feng, Y. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J. Obstet. Gynaecol. Res., 2012, 38(8), 1077-1085.
[58]
Sakamoto, H.; Mashima, T.; Kizaki, A.; Dan, S.; Hashimoto, Y.; Naito, M.; Tsuruo, T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood, 2000, 95(10), 3214-3218.
[59]
Sakamoto, H.; Mashima, T.; Sato, S.; Hashimoto, Y.; Yamori, T.; Tsuruo, T. Selective activation of apoptosis program by Sp-bromobenzylglutathione cyclopentyl diester in glyoxalase I-overexpressing human lung cancer cells. Clin. Cancer Res., 2001, 7(8), 2513-2518.
[60]
Al-Shar’i, N.; Hassan, M.; Al-Balas, Q.; Almaaytah, A. Identification of possible glyoxalase ii inhibitors as anticancer agents by a customized 3D structure-based pharmacophore model. Jordan J. Pharmaceut. Sci., 2015, 8(2)
[61]
Armstrong, R.N. Mechanistic diversity in a metalloenzyme superfamily†. Biochemistry, 2000, 39(45), 13625-13632.
[62]
Kargatov, A.M.; Boshkova, E.A.; Chirgadze, Y.N. Novel approach for structural identification of protein family: glyoxalase I. J. Biomol. Struct. Dyn., 2017, 1-14.
[63]
Thornalley, P.J. Glyoxalase I--structure, function and a critical role in the enzymatic defence against glycation. Biochem. Soc. Transact., 2003, 31(Pt 6), 1343-1348.
[64]
Cameron, A.D.; Olin, B.; Ridderstrom, M.; Mannervik, B.; Jones, T.A. Crystal structure of human glyoxalase I--evidence for gene duplication and 3D domain swapping. EMBO J., 1997, 16(12), 3386-3395.
[65]
Chiba, T.; Ohwada, J.; Sakamoto, H.; Kobayashi, T.; Fukami, T.A.; Irie, M.; Miura, T.; Ohara, K.; Koyano, H. Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(24), 7486-7489.
[66]
Yadav, A.; Kumar, R.; Sunkaria, A.; Singhal, N.; Kumar, M.; Sandhir, R. Evaluation of potential flavonoid inhibitors of glyoxalase-I based on virtual screening and in vitro studies. J. Biomol. Struct. Dynam., 2015, 1, 1-15.
[67]
N-Hydroxypyridone-based glyoxalase I inhibitors mimicking binding interactions of the substrate.http://www rcsb org/structure/ 3W0U.
[68]
Al-Balas, Q.; Hassan, M.; Al Jabal, G.; Al-Shar’i, N.; Almaaytah, A.; El-Elimat, T. Novel thiazole carboxylic acid derivatives possessing a “zinc binding feature” as potential human glyoxalase-i inhibitors. Lett. Drug Design . Discov., 2017, 14(11), 1324-1334.
[69]
Al-Balas, Q.; Hassan, M.; Al-Oudat, B.; Alzoubi, H.; Mhaidat, N.; Almaaytah, A. Generation of the first structure-based pharmacophore model containing a selective “zinc binding group” feature to identify potential glyoxalase-1 inhibitors. Mol.(Basel, Switzerland), 2012, 17(12), 13740-13758.
[70]
Schasteen, C.S.; Reed, D.J. Involvement of arginine residues in glutathione binding to yeast glyoxalase I. Biochim. Biophys. Acta, 1983, 742(2), 419-425.
[71]
Vander Jagt, D.L.; Han, L.P. Deuterium isotope effects and chemically modified coenzymes as mechanism probes of yeast glyoxalase-I. Biochemistry, 1973, 12(25), 5161-5167.
[72]
Ridderstrom, M.; Cameron, A.D.; Jones, T.A.; Mannervik, B. Involvement of an active-site Zn2+ ligand in the catalytic mechanism of human glyoxalase I. J. Biol. Chem., 1998, 273(34), 21623-21628.
[73]
Vince, R.; Daluge, S.; Wadd, W.B. Inhibition of glyoxalase I by S-substituted glutathiones. J. Med. Chem., 1971, 14(5), 402-404.
[74]
More, S.S.; Vince, R. A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I. Bioorg. Med. Chem. Lett., 2006, 16(23), 6039-6042.
[75]
Lo, T.W.C.; Thornalley, P.J. Inhibition of proliferation of human leukaemia 60 cells by diethyl esters of glyoxalase inhibitors in vitro. Biochem. Pharmacol., 1992, 44(12), 2357-2363.
[76]
Hamilton, D.S.; Creighton, D.J. Inhibition of glyoxalase I by the enediol mimic S-(N-hydroxy-N-methylcarbamoyl)glutathione. The possible basis of a tumor-selective anticancer strategy. J. Biol. Chem., 1992, 267(35), 24933-24936.
[77]
More, S.S.; Vince, R. Inhibition of Glyoxalase I: The first low-nanomolar tight-binding inhibitors. J. Med. Chem., 2009, 52(15), 4650-4656.
[78]
Swati, S.; More, R.V. Design, synthesis, and binding studies of bidentate Zn-chelating peptidic inhibitors of glyoxalase-I. Bioorg. Med. Chem. Lett., 2007, 17, 3793-3797.
[79]
Huntley, C.F.M.; Hamilton, D.S.; Creighton, D.J.; Ganem, B. Reaction of COTC with Glutathione: Structure of the Putative Glyoxalase I Inhibitor. Org. Lett., 2000, 2(20), 3143-3144.
[80]
Zheng, Z-B.; Creighton, D.J. Bivalent Transition-State Analogue Inhibitors of Human Glyoxalase I. Org. Lett., 2003, 5(25), 4855-4858.
[81]
Holewinski, R.J.; Creighton, D.J. Inhibition by active site directed covalent modification of human glyoxalase I. Bioorg. Med. Chem., 2014, 22(13), 3301-3308.
[82]
Takasawa, R.; Takahashi, S.; Saeki, K.; Sunaga, S.; Yoshimori, A.; Tanuma, S. Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg. Med. Chem., 2008, 16(7), 3969-3975.
[83]
Takasawa, R.; Saeki, K.; Tao, A.; Yoshimori, A.; Uchiro, H.; Fujiwara, M.; Tanuma, S-i. Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg. Med. Chem., 2010, 18(19), 7029-7033.
[84]
Takasawa, R.; Tao, A.; Saeki, K.; Shionozaki, N.; Tanaka, R.; Uchiro, H.; Takahashi, S.; Yoshimori, A.; Tanuma, S-i. Discovery of a new type inhibitor of human glyoxalase I by myricetin-based 4-point pharmacophore. Bioorg. Med. Chem. Lett., 2011, 21(14), 4337-4342.
[85]
Takasawa, R.; Akahane, H.; Tanaka, H.; Shimada, N.; Yamamoto, T.; Uchida-Maruki, H.; Sai, M.; Yoshimori, A.; Tanuma, S.I. Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I. Bioorg. Med. Chem. Lett., 2017, 27(5), 1169-1174.
[86]
Zhang, H.; Zhai, J.; Zhang, L.; Li, C.; Zhao, Y.; Chen, Y.; Li, Q.; Hu, X.P. In Vitro Inhibition of Glyoxalase capital I, Ukrainian by Flavonoids: New insights from crystallographic analysis. Curr. Top. Med. Chem., 2016, 16(4), 460-466.
[87]
Al-Balas, Q.A.; Hassan, M.A.; Al-Shar’i, N.A.; El-Elimat, T.; Almaaytah, A.M. Computational and experimental exploration of the structure-activity relationships of flavonoids as potent glyoxalase-I inhibitors. Drug Develop. Res., 2017.
[88]
Liu, M.; Yuan, M.; Luo, M.; Bu, X.; Luo, H-B.; Hu, X. Binding of curcumin with glyoxalase I: Molecular docking, molecular dynamics simulations, and kinetics analysis. Biophys. Chem., 2010, 147(1-2), 28-34.
[89]
Yuan, M.; Luo, M.; Song, Y.; Xu, Q.; Wang, X.; Cao, Y.; Bu, X.; Ren, Y.; Hu, X. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg. Med. Chem., 2011, 19(3), 1189-1196.
[90]
Zhai, J.; Zhang, H.; Zhang, L.; Zhao, Y.; Chen, S.; Chen, Y.; Peng, X.; Li, Q.; Yuan, M.; Hu, X. Zopolrestat as a Human Glyoxalase I Inhibitor and Its Structural Basis. ChemMedChem, 2013, 8(9), 1462-1464.
[91]
Al-Balas, Q.A.; Hassan, M.A.; Al-Shar’i, N.A.; Mhaidat, N.M.; Almaaytah, A.M.; Al-Mahasneh, F.M.; Isawi, I.H. Novel glyoxalase-I inhibitors possessing a “zinc-binding feature” as potential anticancer agents. Drug Design Develop. Ther., 2016, 10, 2623-2629.
Download PDF Flyer